Barclays’s Neon Therapeutics, Inc. Common Stock NTGN Stock Holding History

Barclays’s Portfolio NTGN Stock Details NTGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-4,749	Closed	-$13K	–	6566
2020 Q1	$13K	Sell	4,749 -9,665	-67%	-$15.8K	﹤0.01%	5769
2019 Q4	$17K	Buy	14,414 +7,239	+101%	+$11.6K	﹤0.01%	6021
2019 Q3	$12K	Sell	7,175 -3,980	-36%	-$12.1K	﹤0.01%	6326
2019 Q2	$52K	Sell	11,155 -701	-6%	-$3.92K	﹤0.01%	6076
2019 Q1	$77K	Buy	11,856 +10,109	+579%	+$52.9K	﹤0.01%	5566
2018 Q4	$9K	Sell	1,747 -2,362	-57%	-$16.5K	﹤0.01%	6238
2018 Q3	$35K	Buy	+4,109	New	+$45.5K	﹤0.01%	6261

Barclays's NTGN Position: Q2 2020 in Review

Barclays sold out of Neon Therapeutics, Inc. Common Stock (NTGN) in Q2 2020, closing a stake of 4,749 shares — an estimated $13K sold.

Barclays first reported a position in NTGN in Q3 2018 and held it in 7 quarters. The position peaked at $77K in Q1 2019. 0 funds tracked by Wall St. Rank hold NTGN as of Q2 2020.

Barclays reported no remaining Neon Therapeutics, Inc. Common Stock position as of Q2 2020 after selling out during the quarter.
Barclays sold 4,749 Neon Therapeutics, Inc. Common Stock shares in Q2 2020, an estimated $13K.
Barclays first reported a position in Neon Therapeutics, Inc. Common Stock in Q3 2018 and held it in 7 quarters.
Barclays's Neon Therapeutics, Inc. Common Stock position peaked at $77K in Q1 2019.
0 funds tracked by Wall St. Rank held Neon Therapeutics, Inc. Common Stock as of Q2 2020.

Based on Barclays's 13F filing for Q2 2020, filed 12 Aug 2020.